For patients with advanced prostate cancer, treatment decisions rarely happen just once. A therapy works, then stops working. A clinical trial ends. New scans reveal new questions. What comes next is often less certain than what came before.
That was the reality facing a Canadian patient, Mr. Wayne, diagnosed with metastatic castration-resistant prostate cancer. After several lines of treatment and participation in a radioligand therapy trial, he found himself searching for another option. Eventually, the search took him across the Atlantic to Austria, where, with the help of Airomedical, he received Actinium-225 PSMA therapy. His story opens a window into what can happen when patients start to seek specialized treatment outside of their own healthcare system.
Why Looking Abroad Became an Option
Mr. Wayne’s search for treatment outside Canada didn’t begin with a desire to travel. It began with the reality of living with metastatic castration-resistant prostate cancer, a stage of the disease where treatment plans often need to change as the cancer adapts or progresses.
Prostate cancer continues to be one of the most prevalent cancers diagnosed among men. According to the Canadian Cancer Society, an estimated 27,900 Canadian men were expected to be diagnosed with prostate cancer in 2024. Many cases are caught early and treated successfully, but advanced disease may require multiple lines of treatment over time.
Mr. Wayne had already been through several therapies, including androgen deprivation therapy, radiation treatment, and participation in a radioligand therapy study. Like many patients facing advanced cancer, he became familiar with a difficult reality: a treatment that works today may not remain effective indefinitely.
Eventually, follow-up imaging showed that the cancer was progressing. With the Lu-177 trial no longer an option, Wayne began looking into other treatments that might still be available to him. One of them was Actinium-225 PSMA therapy.
At that point, it was no longer just a medical challenge. It was also a practical matter. Some treatment options were available only through selected providers, so finding the right therapy could mean looking beyond national borders.
Learning About Actinium-225 PSMA Therapy
After leaving the Lu-177 study, Mr. Wayne found himself in a position familiar to many people living with advanced cancer. The treatment path that had seemed clear only months before was no longer available, and the next step was far from obvious.
One term kept coming up in his search: Actinium-225. The therapy is being studied as a targeted option for some patients with advanced prostate cancer, particularly when previous treatments have stopped working well. Prostate cancer affects a large number of men around the world. According to the International Agency for Research on Cancer (IARC), more than 1.4 million new cases were diagnosed globally in 2022, which helps explain the ongoing search for additional treatment options.
Actinium-225 PSMA therapy is part of a newer class of treatments called radioligand therapies. This approach delivers radiation directly to cancer cells that express PSMA, a protein commonly found on advanced prostate cancer cells. Instead of impacting large areas of the body, this treatment is designed to target tumor cells more precisely.
The interest in radioligand therapy has increased over the last years, as the researchers are looking for new options for patients with advanced disease. For patients with cancer that has progressed despite prior treatment, investigational therapies such as Actinium-225 can be another option to discuss with specialists.
To understand Actinium-225 treatment better, Mr. Wayne reviewed available information and spoke with doctors about whether the therapy might be suitable for his situation. The answer depended on far more than interest alone. Eligibility, medical records, imaging results, and access to an experienced treatment center all had to be considered.
For patients with metastatic castration-resistant prostate cancer, timing often matters. Decisions that might be postponed in other situations sometimes need to be made relatively quickly. As Mr. Wayne continued gathering information, the focus shifted from learning about the therapy itself to finding a medical center that could provide it.
Making the Trip to Austria
Learning about Actinium-225 was one thing. Getting access to it was another.
By this stage, Mr. Wayne had already spent months moving between treatments, consultations, and follow-up scans. What came next required looking beyond Canada.
Before treatment could proceed, doctors needed a current PSMA PET-CT scan to confirm that the cancer remained a suitable target for PSMA-directed therapy. Instead of arranging additional testing at home, the scan was built into the treatment schedule in Vienna.
Airomedical connected Mr. Wayne with MINUTE Medical Vienna, where he was treated under the care of Prof. Dr. Markus Hartenbach. The company also helped coordinate communication with the clinic and organize the practical details leading up to treatment.
The PET-CT scan was performed shortly before the planned procedure. Once the results confirmed eligibility, Mr. Wayne moved forward with Actinium-225 therapy.
Unlike a lengthy hospital stay, the treatment was performed on an outpatient basis. That allowed Mr. Wayne to focus on the medical side of the visit rather than spending additional time navigating inpatient care in an unfamiliar healthcare system.
Coordinating Treatment Across Borders
Treatment was only one part of the equation. There were consultations to schedule, medical records to review, and travel plans to coordinate within a relatively short timeframe.
Mr. Wayne was ultimately referred to MINUTE Medical Vienna, where he came under the care of Prof. Dr. Markus Hartenbach. Airomedical.com helped facilitate communication with the clinic and coordinate the steps leading up to treatment.
The planning process involved more than booking appointments. Medical records had to be evaluated, eligibility confirmed, and diagnostic requirements addressed before therapy could move forward.
One complication involved imaging. Mr. Wayne did not have a recent PSMA PET-CT scan prior to travel. Rather than delaying treatment while additional testing was arranged in Canada, the scan was incorporated into the treatment schedule in Vienna. The results allowed the medical team to confirm that Actinium-225 therapy remained an appropriate option before proceeding.
By the time Mr. Wayne arrived in Vienna, most of the work had already been done. The clinic had his medical records, consultations had taken place, and the remaining tests were scheduled around the treatment.
After the Treatment
By the time Mr. Wayne received Actinium-225 therapy in Vienna, the treatment itself had become only one part of a much longer story. Months earlier, he had been evaluating clinical trials, reviewing treatment options, and trying to determine what possibilities still remained available to him.
Traveling to Austria had never been part of the original plan. It only became an option after other treatments had run their course and Actinium-225 entered the conversation. Getting there involved consultations, medical records, imaging requirements, and plenty of coordination on both sides of the Atlantic.
By the time treatment took place, Mr. Wayne had spent months gathering information and weighing his options. The trip to Austria was not part of the original plan. It became part of the plan only after other paths had narrowed and Actinium-225 emerged as a possibility worth exploring.
Looking Back on the Experience
A few months earlier, Mr. Wayne was focused on a very different set of options. Austria was not under consideration, and Actinium-225 was not part of the conversation. Both appeared later, after other treatment avenues had been exhausted.
The path from Canada to Vienna was anything but direct. It involved scans, consultations, paperwork, and long stretches of waiting for answers. Like many people dealing with a serious illness, Mr. Wayne spent a considerable amount of time simply trying to figure out what was realistically available.
According to the Medical Tourism Association, an estimated 14 million people travel abroad for medical care each year. Mr. Wayne became one of them when his search eventually led him to Austria and a treatment center prepared to offer Actinium-225 therapy.
What started as another round of research turned into a medical tourism success story. Not because the trip itself was remarkable, but because it gave him access to an option he had been unable to pursue before.
More Than a Trip for Treatment
Not every patient with advanced prostate cancer will follow the same path. But Mr. Wayne’s experience shows how quickly treatment decisions can evolve and how far some patients will travel when searching for the next available option.
Months earlier, Austria hadn’t been part of the conversation. Neither had Actinium-225. Both entered the picture only after previous treatments stopped delivering the hoped-for results.
For Mr. Wayne, the decision wasn’t about where to go. It was about what options remained.
While every patient’s circumstances are different, Mr. Wayne’s experience illustrates some of the practical, medical, and logistical decisions that can accompany treatment abroad.
References
- Canadian Cancer Society. Prostate Cancer Statistics in Canada. 2024.
- International Agency for Research on Cancer (IARC), World Health Organization. Global Cancer Observatory: Prostate Cancer Fact Sheet. Lyon, France: IARC. 2024.
- MUDr. Popel A. & Dr. Ahmed F. Actinium-225 PSMA Therapy for Prostate Cancer. Airomedical. Updated 2026.
- National Cancer Institute. Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S. Department of Health and Human Services. 2025.
- M.D. Kaminska O. Nuclear Medicine in Austria: Canadian Patient Treated with Actinium-225 for Metastatic Prostate Cancer. Airomedical. Updated 2026.
- Medical Tourism Association. Medical Tourism Facts and Statistics. 2025.
